Back to search

Article

Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer

2022-09-01

Abstract excerpt

<title>Abstract</title><p>Castration-resistant prostate cancer (CRPC) is the main driving force of mortality in prostate cancer patients. Among the parameters contributing to the progression of CRPC and treatment failure, elevation of the steroidogenic enzyme AKR1C3 and androgen receptor variant 7 (AR-V7) are frequently reported. The AKR1C3/AR-V7 complex has been recognized as a major driver for drug resistance in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8eea8b30-57f8-5061-9fb7-06d4ae374eca
DOI
10.21203/rs.3.rs-1991622/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancerDOI 10.21203/rs.3.rs-1991622/v1
Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer GrowthSemantic proximity
The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancerSemantic proximity
A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate CancerSemantic proximity
Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7.Semantic proximity
ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.Semantic proximity
LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance.Semantic proximity
Biochanin-A inhibits the activity of androgen receptor mutants to suppress the development of prostate cancerSemantic proximity
Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate CancerSemantic proximity
Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).Semantic proximity
Evaluating Gliclazide as a Safer Alternative Treatment for Castration- Resistant Prostate Cancer via lncRNA-Mediated Androgen Receptor InteractionsSemantic proximity
LncRNA SNHG4 promotes prostate cancer cell survival and resistance to enzalutamide through a let-7a/RREB1 positive feedback loop and a ceRNA networkSemantic proximity
Reciprocal regulation between RACGAP1 and AR contributes to endocrine therapy resistance in prostate cancerSemantic proximity
Select a neighboring publication to make it the new centre.